Inhibrx Biosciences, Inc. (INBX) Profit Margins

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

INBXInhibrx Biosciences, Inc.Follow INBX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 1.4B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 13 Nov, in 20 days

Line	FY2024 Dec 24	FY2025 Dec 25	TTM Jun 26
Operating margin	-165724.0%	-10386.5%	—
Net margin	843786.0%	-10773.5%	—
FCF margin	-98503.0%	-9986.5%	—

USD millions · SEC XBRL

Every figure on this page comes from Inhibrx Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.